These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 32312344)

  • 21. Symptom networks in acute depression across bipolar and major depressive disorders: A network analysis on a large, international, observational study.
    Corponi F; Anmella G; Verdolini N; Pacchiarotti I; Samalin L; Popovic D; Azorin JM; Angst J; Bowden CL; Mosolov S; Young AH; Perugi G; Vieta E; Murru A
    Eur Neuropsychopharmacol; 2020 Jun; 35():49-60. PubMed ID: 32409261
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Serum amyloid P component level is associated with clinical response to escitalopram treatment in patients with major depressive disorder.
    Yang J; Zhou J; Zhou J; Wang H; Sun Z; Zhu X; He Y; Wong AHC; Liu F; Wang G
    J Psychiatr Res; 2022 Feb; 146():172-178. PubMed ID: 34995992
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Open-label treatment with desvenlafaxine in postmenopausal women with major depressive disorder not responding to acute treatment with desvenlafaxine or escitalopram.
    Soares CN; Thase ME; Clayton A; Guico-Pabia CJ; Focht K; Jiang Q; Kornstein SG; Ninan PT; Kane CP
    CNS Drugs; 2011 Mar; 25(3):227-38. PubMed ID: 21323394
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An evaluation of sexual functioning in employed outpatients with major depressive disorder treated with desvenlafaxine 50 mg or placebo.
    Clayton AH; Reddy S; Focht K; Musgnung J; Fayyad R
    J Sex Med; 2013 Mar; 10(3):768-76. PubMed ID: 22905811
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety, Tolerability, and Efficacy of Desvenlafaxine in Children and Adolescents with Major Depressive Disorder: Results from Two Open-Label Extension Trials.
    Atkinson S; Thurman L; Ramaker S; Buckley G; Jones SR; England R; Wajsbrot D
    CNS Spectr; 2019 Oct; 24(5):496-506. PubMed ID: 30419989
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of 50 and 100 mg desvenlafaxine versus placebo on sexual function in patients with major depressive disorder: a meta-analysis.
    Clayton AH; Hwang E; Kornstein SG; Tourian KA; Cheng RF; Abraham L; Mele L; Boucher M
    Int Clin Psychopharmacol; 2015 Nov; 30(6):307-15. PubMed ID: 26230270
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Improvements in quality of life with desvenlafaxine 50mg/d vs placebo in employed adults with major depressive disorder.
    Endicott J; Lam RW; Hsu MA; Fayyad R; Boucher M; Guico-Pabia CJ
    J Affect Disord; 2014 Sep; 166():307-14. PubMed ID: 25012446
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Predictors of functional response and remission with desvenlafaxine 50 mg and 100 mg: a pooled analysis of randomized, placebo-controlled studies in patients with major depressive disorder.
    Soares CN; Wajsbrot DB; Boucher M
    CNS Spectr; 2020 Jun; 25(3):363-371. PubMed ID: 31060632
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of metabolic syndrome and thyroid hormone on efficacy of desvenlafaxine 50 and 100 mg/d in major depressive disorder.
    McIntyre RS; Fayyad R; Mackell JA; Boucher M
    Curr Med Res Opin; 2016; 32(3):587-99. PubMed ID: 26709542
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Investigation of miR-1202, miR-135a, and miR-16 in Major Depressive Disorder and Antidepressant Response.
    Fiori LM; Lopez JP; Richard-Devantoy S; Berlim M; Chachamovich E; Jollant F; Foster J; Rotzinger S; Kennedy SH; Turecki G
    Int J Neuropsychopharmacol; 2017 Aug; 20(8):619-623. PubMed ID: 28520926
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cerebral cortical thickness after treatment with desvenlafaxine succinate in major depressive disorder.
    Suh JS; Minuzzi L; Cudney LE; Maich W; Eltayebani M; Soares CN; Frey BN
    Neuroreport; 2019 Mar; 30(5):378-382. PubMed ID: 30741785
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Single i.v. ketamine augmentation of newly initiated escitalopram for major depression: results from a randomized, placebo-controlled 4-week study.
    Hu YD; Xiang YT; Fang JX; Zu S; Sha S; Shi H; Ungvari GS; Correll CU; Chiu HF; Xue Y; Tian TF; Wu AS; Ma X; Wang G
    Psychol Med; 2016 Feb; 46(3):623-35. PubMed ID: 26478208
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An investigation of cortical thickness and antidepressant response in major depressive disorder: A CAN-BIND study report.
    Suh JS; Minuzzi L; Raamana PR; Davis A; Hall GB; Harris J; Hassel S; Zamyadi M; Arnott SR; Alders GL; Sassi RB; Milev R; Lam RW; MacQueen GM; Strother SC; Kennedy SH; Frey BN
    Neuroimage Clin; 2020; 25():102178. PubMed ID: 32036277
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of a Machine Learning Model Based on Pretreatment Symptoms and Electroencephalographic Features to Predict Outcomes of Antidepressant Treatment in Adults With Depression: A Prespecified Secondary Analysis of a Randomized Clinical Trial.
    Rajpurkar P; Yang J; Dass N; Vale V; Keller AS; Irvin J; Taylor Z; Basu S; Ng A; Williams LM
    JAMA Netw Open; 2020 Jun; 3(6):e206653. PubMed ID: 32568399
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The effects of vortioxetine on cognitive dysfunction in patients with inadequate response to current antidepressants in major depressive disorder: A short-term, randomized, double-blind, exploratory study versus escitalopram.
    Vieta E; Sluth LB; Olsen CK
    J Affect Disord; 2018 Feb; 227():803-809. PubMed ID: 29673132
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Retrospective analysis of suicidality in patients treated with the antidepressant desvenlafaxine.
    Tourian KA; Padmanabhan K; Groark J; Ninan PT
    J Clin Psychopharmacol; 2010 Aug; 30(4):411-6. PubMed ID: 20631558
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Residual symptoms in depressed outpatients who respond by 50% but do not remit to antidepressant medication.
    McClintock SM; Husain MM; Wisniewski SR; Nierenberg AA; Stewart JW; Trivedi MH; Cook I; Morris D; Warden D; Rush AJ
    J Clin Psychopharmacol; 2011 Apr; 31(2):180-6. PubMed ID: 21346613
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy outcomes in the MDD-1 India study: First episode major depressive disorder outcomes in antidepressant-treated real-world patients in India.
    Andrade C; De Sousa A; Shah N
    J Psychopharmacol; 2020 Oct; 34(10):1098-1104. PubMed ID: 32684093
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Differential change on depressive symptom factors with antidepressant medication and cognitive behavior therapy for major depressive disorder.
    Dunlop BW; Cole SP; Nemeroff CB; Mayberg HS; Craighead WE
    J Affect Disord; 2018 Mar; 229():111-119. PubMed ID: 29306690
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Correlates of residual fatigue in patients with major depressive disorder: The role of psychotropic medication.
    Chung KF; Yu YM; Yeung WF
    J Affect Disord; 2015 Nov; 186():192-7. PubMed ID: 26247911
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.